Shamburg News · 8-K filed Nov 10, 2026, 4:05 PM EST

Gain Therapeutics Reports Third Quarter 2026 Results and Rexaceract Corporate Update

GANX · Gain Therapeutics, Inc.

  • Earnings
  • Other event
  • Materiality: high

Gain Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $0.07 per share, basic and diluted, compared with $0.15 per share a year earlier. Research and development expenses were $1.4 million compared with $2.8 million in the prior-year quarter, and cash and cash equivalents were $11.7 million as of September 30, 2026. The company also reported long-term open-label data for rexaceract in Parkinson's disease and expects to begin a Phase 2 trial in Q1 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-125159.

Written from the filing by Shamburg Markets. Figures are as reported by the company.